Home
Live Updates
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer : vimarsana.com
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in...
Related Keywords
United States ,
Canada ,
,
Merck Research Laboratories ,
European Society For Medical Oncology ,
Exchange Commission ,
Statement Of Merck Co Inc ,
Linkedin ,
Taiho Pharmaceutical Co ,
Merck Co Inc ,
Astex Pharmaceuticals United Kingdom ,
Instagram ,
Facebook ,
Otsuka Pharmaceutical Co Ltd ,
Youtube ,
Twitter ,
Marjorie Green ,
Merck Research ,
European Society ,
Medical Oncology ,
Taiho Pharmaceutical ,
Astex Pharmaceuticals ,
United Kingdom ,
Selected Important Safety ,
Important Safety Information ,
Fatal Immune Mediated Adverse ,
Which Can Present With Diabetic ,
Nervous System ,
Connective Tissue ,
Patients With Multiple ,
Neck Squamous Cell ,
Bacillus Calmette Guerin ,
Mismatch Repair Deficient ,
Mismatch Repair Deficient Colorectal ,
Looking Statement ,
Securities Litigation Reform Act ,
Annual Report ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.